- Adami S, Libanati C, Boonen S, Cummings S R, Ho P R, Wang A, Siris E, Lane J; FREEDOM Fracture-Healing Writing Group, Adachi J D, Bhandari M, de Gregorio L, Gilchrist N, Lyritis G, Möller G, Palacios S, Pavelka K, Heinrich R, Roux C, Uebelhart D. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture healing: results from the FREEDOM trial. J Bone Joint Surg Am 2012; 94 (23): 2113–9.
- Agarwala S, Jain D, Joshi V R, Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatol 2005; 44 (3): 352–9.
- Aspenberg P. Denosumab and atypical femoral fractures. Acta Orthop 2014; 85 (1): 1–2.
- Camacho N P, Raggio C L, Doty S B, Root L, Zraick V, Ilg W A, Toledano T R, Boskey A L. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int 2001; 69 (2): 94–101.
- Catterall A. The natural history of Perthes’ disease. J Bone Joint Surg Br. 1971; 53 (1): 37–53.
- Gerstenfeld L C, Sacks D J, Pelis M, Mason Z D, Graves D T, Barrero M, Ominsky M S, Kostenuik P J, Morgan E F, Einhorn T A. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009; 24 (2): 196–208.
- Grasemann C, Schündeln M M, Hövel M, Schweiger B, Bergmann C, Herrmann R, Wieczorek D, Zabel B, Wieland R, Hauffa B P. Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget’s disease. J Clin Endocrinol Metab 2013; 98 (8): 3121–6.
- Hoyer-Kuhn H, Franklin J, Allo G, Kron M, Netzer C, Eysel P, Hero B, Schoenau E, Semler O. Safety and efficacy of denosumab in children with osteogenesis imperfecta - a first prospective trial. J Musculoskelet Neuronal Interact 2016; 16 (1): 24–32.
- Hyman J E, Trupia E P, Wright M L, Matsumoto H, Jo C H, Mulpuri K, Joseph B, Kim H K and the International Perthes Study Group Members. Interobserver and intraobserver reliability of the modified Waldenström classification system for staging of Legg-Calvé-Perthes disease. J Bone Joint Surg Am 2015; 97 (8): 643–50.
- Joseph B, Varghese G, Mulpuri K, Narasimha Rao K, Nair NS. Natural evolution of Perthes‘disease: a study of 610 children under 12 years of age at disease onset. J Pediatr Orthop 2003; 23 (5): 590–600.
- Kim H K, Randall T S, Bian H, Jenkins J, Garces A, Bauss F. Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. J Bone Joint Surg Am 2005; 87 (3): 550–7.
- Kim H K, Morgan-Bagley S, Kostenuik P. RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis. J Bone Miner Res 2006; 21 (12): 1946–54.
- Kim H K. Pathophysiology and new strategies for the treatment of Legg-Calvé-Perthes disease. J Bone Joint Surg Am 2012; 94 (7): 659–69.
- Kobayashi E, Setsu N. Osteosclerosis induced by denosumab. Lancet 2015; 385 (9967): 539.
- Lange T, Stehling C, Fröhlich B, Klingenhöfer M, Kunkel P, Schneppenheim R, Escherich G, Gosheger G, Hardes J, Jürgens H, Schulte T L. Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts. Eur Spine J 2013; 22 (6): 1417–22.
- Lee Y K, Ha Y C, Cho Y J, Suh K T, Kim S Y, Won Y Y, Min B W, Yoon T R, Kim H J, Koo K H. Does zoledronate prevent femoral head collapse from osteonecrosis? A prospective, randomized, open-label, multicenter study. J Bone Joint Surg Am 2015; 97 (14): 1142–8.
- Lepola V T, Hannuniemi R, Kippo K, Lauren L, Jalovaara P, Vaananen H K. Long-term effects of clodronate on growing rat bone. Bone 1996; 18 (2): 191–196.
- Meiss A L. MRT zur Diagnostik des Containment-Verlustes beim Morbus Perthes. Medizinisch-Orthopädische Technik 2001; 121 (2): 47–54.
- Ombrédanne L. Précis clinique et opératoire de chirurgie infantile. Masson et Cie, Paris, 1923; II: 855–6.
- Perkins G. Signs by which to diagnose congenital dislocation of the hip. Lancet 1928; 1: 648–50.
- Salter R B, Thompson G H. Legg-Calvé-Perthes‘disease. The prognostic significance of the subchondral fracture and a two-group classification of the femoral head involvement. J Bone Joint Surg Am 1984; 66 (4): 479–89.
- Schilcher J, Aspenberg P. Atypical fracture of the femur in a patient using denosumab – a case report. Acta Orthop 2014; 85 (1): 6–7.
- Setsu N, Kobayashi E, Asano N, Yasui N, Kawamoto H, Kawai A, Horiuchi K. Severe hypercalcemia following denosumab treatment in a juvenile patient. J Bone Miner Metab 2016; 34 (1): 118–22.
- Stulberg S D, Cooperman D R, Wallensten R. The natural history of Legg-Calvé-Perthes disease. J Bone Joint Surg Am 1981; 63 (7): 1095–108.
- Wang H D, Boyce A M, Tsai J Y, Gafni R I, Farley F A, KasaVubu J Z, Molinolo A A, Collins M T. Effects of denosumab treatment and discontinuation on human growth plates. J Clin Endocrinol Metab 2014; 99 (3): 891–897.
- Young M L, Little D G, Kim H K. Evidence for using bisphosphonate to treat Legg-Calvé-Perthes disease. Clin Orthop Relat Res 2012; 470 (9): 2462–75.
- Choose new content alerts to be informed about new research of interest to you
- Easy remote access to your institution's subscriptions on any device, from any location
- Save your searches and schedule alerts to send you new results
- Export your search results into a .csv file to support your research